Indication
Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Loading your page…
Loading your page…
Asthma
Marketing Authorisation Holder: Novartis Europharm Limited
EMA Authorisation: 30/05/2020
INN: indacaterol;mometasone
AI Drug & Interaction Analysis
Free account required
Ask Osler about Atectura Breezhaler: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.